(122) explored the role of pargyline (an LSD1 inhibitor) and SAHA in breast cancer, the results demonstrated that both pargyline and SAHA suppressed cell proliferation and induced apoptosis through inhibiting HDAC5. Here, HDAC5 is linked to breast carcinoma.